Compile Data Set for Download or QSAR
Report error Found 8 Enz. Inhib. hit(s) with all data for entry = 1422
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Blueprint Medicines

US Patent
LigandPNGBDBM84747(Vandetanib | (B) ZD6474 | US10155768, Vandetanib |...)
Affinity DataIC50: 1.20nMAssay Description:A compound described herein can be tested in vitro for inhibition of wild-type RET and various mutant RET kinases, including e.g., RET V804L, RET V80...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Blueprint Medicines

US Patent
LigandPNGBDBM50363397(CHEMBL1946170 | REGORAFENIB | US10183928, Regorafe...)
Affinity DataIC50: 5.10nMAssay Description:A compound described herein can be tested in vitro for inhibition of wild-type RET and various mutant RET kinases, including e.g., RET V804L, RET V80...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Blueprint Medicines

US Patent
LigandPNGBDBM16673(Xarelto | BAY439006 | CHEMBL1336 | BAY 43-9006 | 4...)
Affinity DataIC50: 7.90nMAssay Description:A compound described herein can be tested in vitro for inhibition of wild-type RET and various mutant RET kinases, including e.g., RET V804L, RET V80...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Blueprint Medicines

US Patent
LigandPNGBDBM50363397(CHEMBL1946170 | REGORAFENIB | US10183928, Regorafe...)
Affinity DataIC50: 29.8nMAssay Description:A compound described herein can be tested in vitro for inhibition of wild-type RET and various mutant RET kinases, including e.g., RET V804L, RET V80...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Blueprint Medicines

US Patent
LigandPNGBDBM50021574(CHEBI:72317 | CABOZANTINIB | BMS-907351 | Cometriq...)
Affinity DataIC50: 46nMAssay Description:A compound described herein can be tested in vitro for inhibition of wild-type RET and various mutant RET kinases, including e.g., RET V804L, RET V80...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Blueprint Medicines

US Patent
LigandPNGBDBM16673(Xarelto | BAY439006 | CHEMBL1336 | BAY 43-9006 | 4...)
Affinity DataIC50: 95.2nMAssay Description:A compound described herein can be tested in vitro for inhibition of wild-type RET and various mutant RET kinases, including e.g., RET V804L, RET V80...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Blueprint Medicines

US Patent
LigandPNGBDBM50021574(CHEBI:72317 | CABOZANTINIB | BMS-907351 | Cometriq...)
Affinity DataIC50: 219nMAssay Description:A compound described herein can be tested in vitro for inhibition of wild-type RET and various mutant RET kinases, including e.g., RET V804L, RET V80...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Blueprint Medicines

US Patent
LigandPNGBDBM84747(Vandetanib | (B) ZD6474 | US10155768, Vandetanib |...)
Affinity DataIC50: 902nMAssay Description:A compound described herein can be tested in vitro for inhibition of wild-type RET and various mutant RET kinases, including e.g., RET V804L, RET V80...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
US Patent